SCHEMBL348975

SCHEMBL348975

COC(=O)c1ccnc(CO)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.57
KDM4E B2RXH2 2/20 0.57
KDM5C P41229 2/20 0.57
KDM6B O15054 1/20 0.57
KDM2A Q9Y2K7 1/20 0.57
KDM3A Q9Y4C1 1/20 0.57
ALOX15 P16050 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
JMJD6 Q6NYC1 1/20 0.50
NPC1 O15118 1/20 0.49
HPGD P15428 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KDM5B Q9UGL1 4/20 0.47
KDM5A P29375 3/20 0.47
HTT P42858 1/20 0.46
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30740808 1.00 KDM4C (0.57) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL10263738 0.86 KDM4E (0.57) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL31320065 0.86 KDM4E (0.57) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL29700409 0.85 KDM4E (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL22005801 0.85 KDM5C (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL4450004 0.85 KDM4E (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL1007105 0.85 KDM4E (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL16215925 0.85 KDM4C (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL30378291 0.85 KDM4C (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A
SCHEMBL1287072 0.85 KDM4C (0.55) KDM4CKDM4EKDM5CKDM6BKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
WO-2025260159-A1 ISOINDOLINE AND INDOLINE DERIVATIVE COMPOUNDS, COMBINATIONS, PHARMACEUTICAL COMPOSITIONS, MEDICAMENTS, USE OF THE COMPOUNDS AND METHOD OF TREATMENT OF PAIN MICROBIOLÓGICA QUÍMICA E FARMACÊUTICA LTDA. (BR) 2025-12-26 WO disclosed
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION INC (US) 2025-11-20 US disclosed
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use CARMOT THERAPEUTICS INC. (US) 2025-11-04 US disclosed
US-20250325552-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2025-10-23 US disclosed
EP-4251615-B1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2025-10-15 EP disclosed
EP-4563199-A2 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2025-06-04 EP disclosed
US-20250154137-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2025-05-15 US disclosed
US-12275726-B2 Aurora kinase inhibitors and use thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2025-04-15 US disclosed
WO-2024226914-A2 MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF SEPTERNA, INC. (US) 2024-10-31 WO disclosed
WO-2010025179-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2010-03-04 WO disclosed
US-20090325956-A1 Aromatic amine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
EP-0533131-B1 Process for selectively mono-ortho-hydroxy alkylation of 4-substituted pyridine derivatives HOECHST AG (DE) 1995-08-09 EP disclosed
EP-0533132-B1 Process for the oxidation of hydroxymethylpyridine derivatives to pyridine carboxylic acid derivatives HOECHST AG (DE) 1994-11-02 EP disclosed
EP-0300725-B1 Tetrahydroisoquinolin-2-yl derivatives as thromboxane A2 antagonists SMITH KLINE FRENCH LAB (GB) 1994-06-22 EP disclosed
EP-0533130-A1 2-Hydroxymethylpyridines, the corresponding pyridine-N-oxides and derivatives thereof, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-24 EP disclosed
US-5114945-A Spiropiperidine derivatives GLAXO GROUP LIMITED (GB) 1992-05-19 US disclosed
US-4866076-A THROMBOXANE ANTAGONISTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-09-12 US disclosed
EP-0330461-A2 Piperidine derivatives GLAXO GROUP LIMITED (GB) 1989-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325552-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLK, POLH KDM4C 3805/4885KDM4E 3825/4885KDM5C 3583/4885
US-20090325956-A1 Aromatic amine derivative and use thereof SCD, SCD5, SMS KDM4C 554/4885KDM4E 249/4885KDM5C 436/4885
US-20250154137-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GCGR, GIPR KDM4C 3677/4885KDM4E 3526/4885KDM5C 2973/4885
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use GLP1R, GCGR, GIPR KDM4C 3677/4885KDM4E 3526/4885KDM5C 2973/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 KDM4C 1542/4885KDM4E 1440/4885KDM5C 1243/4885
US-12275726-B2 Aurora kinase inhibitors and use thereof AURKA, AURKC, AURKB KDM4C 862/4885KDM4E 585/4885KDM5C 985/4885
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN MEN1, MLLT1, MSI2 KDM4C 786/4885KDM4E 588/4885KDM5C 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.